A study published in the January 21 issue of the World Journal of Gastroenterology found that four strains of probiotics isolated from human feces (E.feacalis, L.acidophilus, C.butyricum and B.adolescentis) relieved symptoms of ulcerative colitis in mice just as well as the commonly-used drug sulfasalazine.
The team of Chinese scientists observed benefits with probiotics on a number of measures such as weight loss, colon length, disease activity index scores, histological scores, proteins and mRNA levels of interleukin-1 and -4 and myeloperoxidase activity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze